Pharmacokinetics/Pharmacodynamics and tolerability of cefiderocol in the clinical setting.

Cefiderocol is a new cephalosporin with a catechol in its chemical structure faciliting its access to the interior of bacteria through iron channels. In addition, it is broadly stable to beta-lactamases. The pharmacokinetic profile is a beta-lactam one: no oral absorption, and with a wide distribution within the vascular space and the interstitial fluid of well vascularized tissues, reaching therapeutic concentrations in the alveolar lavage fluid and within the macrophage. The binding of cefiderocol to human plasma proteins, primarily albumin, is moderate (range 40-60%). The terminal elimination half-life in healthy adult subjects was 2 to 3 hours. Cefiderocol is mainly renally eliminated, so dose adjustments are recommended in subjects with moderate / severe renal impairment, in case of dialysis, and probably in patients with external clearance. Like other beta-lactams, the PK / PD parameter that has been shown to best correlate with efficacy is the efficacy time of unbound plasma concentrations (%fT>MIC), which must be close to 100% to achieve a bactericidal effect. This is possible with 2 g in a 3-hour infusion every 8 hours. In controlled trials appears to be well tolerated, similar to comparators: meropenem or imipenem-cilastatin. Cefiderocol has no apparent clinically significant effect on ECG parameters nor on plasma iron values.

Ceftobiprole: pharmacokinetics and PK/PD profile.

Ceftobiprole shows many similar pharmacokinetic properties to other cephalosporins, except for not being orally bioactive, and that it is administered by IV infusion as the prodrug ceftobiprole medocaril, which is subsequently hydrolyzed in the blood into the active molecule. Distribution focus in extracellular fluid and active antibiotic concentration has been proven in different corporal tissues using dosing regimen of 500 mg intravenous infusion over 2 h every 8 h. Ceftobiprole is eliminated exclusively into the urine, thus the reason why dose adjustment is required for patients with moderate or severe renal impairment, or increased creatinine clearance. However, there is no need for dose adjustments related with other comorbidities and patients' conditions such as age, body weight. Although considering distribution features, molecular weight and dose fraction, increase dosing regimen might be necessary in patients using renal replacement therapy. The half-life of ceftobiprole is more than 3 h, allowing to easily reach optimal PK/PD parameters with the infusion time of 2 h, using the usual dosing regimen.

Bioavailability of two oral fentanyl transmucosal formulations in healthy volunteers: an open-label, crossover, randomised study / Biodisponibilidad de dos formulaciones de fentanilo oral transmucosa en voluntarios sanos: un estudio abierto, cruzado y aleatorizado

Introduction: Oral transmucosal fentanyl citrate (OTFC) was the first product specifically designed for the treatment of breakthrough pain. It is formulated as a sweetened lozenge on a plastic handle (stick) and it is self-administered by the patient, allowing the modulability or flexibility in dosing. Objectives: To prove bioequivalence of a test (T) OTFC product compared to the reference (R) formulation. Material and methods: Open-label, crossover, randomized, single-dose bioequivalence study in healthy volunteers, with two study periods and two sequences, with a washout period of at least 10 days. On each study day, subjects received 400 μg of fentanyl. They were instructed to rub the tablet gently against the buccal mucosa and not to suck on or chew it, and the investigators controlled each administration to ensure that it was consumed during 15 minutes. Given the high pharmacokinetic variability, a two-stage design was established and bioequivalence decision was based on 94.12% confidence intervals of Cmax and AUC0-t geometric means ratio. Results: 36 subjects completed the study according to the protocol. Mean Cmax were similar with both formulations (814.78 pg/ml for T and 781.83 pg/ml for R) and were attained at the same time (40 min. for T and 50 min. for R), and their bioavailability was also very close (AUC0-t: 3920.12 pg.h/ml for T and 3679.39 pg.h/ml for R). Bioequivalence was confirmed for the two primary parameters, Cmax and AUC0-t. No period or sequence effects were observed in any parameter. As bioequivalence was proved in the first phase of the study, it was not necessary to proceed to the second stage. The estimated intraindividual variability was 24.66% and 19.01%, respectively for T and R formulations. Both formulations were well tolerated; 15 mild adverse events were reported. Discussion: The test OTFC product is bioequivalent to the reference one and therefore interchangeable when used clinically. OTFC administration provides faster fentanyl absorption than enteral route and the rate of absorption can be modulated by the administration technique, providing a unique flexibility among all breakthrough pain treatments. The results showed a fast time to maximum concentrations (tmax), in accordance with those originally reported for the reference product, probably favoured by the strict administration technique. Proper patient education is essential to optimize the use of OTFC, as well-trained patients can take advantage of its flexibility to self-controlling pain relief

Introducción: El citrato de fentanilo oral transmucosa (CFOT) fue el primer medicamento diseñado específicamente para tratar el dolor irruptivo. Está formulado como una matriz de polvo comprimido con aplicador de plástico (palito), y el paciente se lo administra, lo que proporciona modulabilidad o flexibilidad de dosis. Objetivos: Probar la bioequivalencia entre el medicamento CFOT test (T) y el de referencia (R). Material y métodos: Estudio abierto, cruzado, aleatorizado, de bioequivalencia a dosis única en voluntarios sanos, con dos periodos y dos secuencias, y con un tiempo de lavado de al menos 10 días. Los sujetos tomaron 400 μg de fentanilo cada día de estudio. Se les instruyó para que restregaran el comprimido contra la mucosa bucal sin chuparlo ni masticarlo, y los investigadores controlaron cada administración para asegurar que se consumía en 15 minutos. Se estableció un diseño en dos etapas por la alta variabilidad farmacocinética esperada, y la decisión de bioequivalencia se basó en los intervalos de confianza al 94,12 % de la razón de las medias geométricas de la Cmax y el AUC0-t. Resultados: 36 sujetos completaron el estudio de acuerdo con el protocolo. Las medias de Cmax fueron similares con ambas formulaciones (814,78 pg/ml para T y 781,83 pg/ml para R) y se alcanzaron al mismo tiempo (40 min para T y 50 min para R), y su biodisponibilidad también fue muy semejante (AUC0-t: 3920,12 pg.h/ml para T y 3679,39 pg.h/ml para R). Se confirmó la bioequivalencia para los dos parámetros principales, Cmax y AUC0-t. No se observaron efecto periodo ni secuencia para ningún parámetro. Como se probó la bioequivalencia en la primera fase del estudio no fue necesario proceder a la segunda fase. La variabilidad intraindividual estimada fue 24,66 y 19,01 %, respectivamente para T y R. Los dos medicamentos fueron bien tolerados; se registraron 5 acontecimientos adversos de intensidad leve. Conclusiones: La formulación CFOT test es bioequivalente con la de referencia, y por tanto son clínicamente intercambiables. La administración de CFOT proporciona una absorción más rápida de fentanilo que la vía enteral y la tasa de absorción puede modularse con la técnica de administración, aportando una flexibilidad única al resto de tratamientos del dolor irruptivo. Los resultados muestran un breve tiempo hasta concentraciones plasmáticas máximas (tmax), coincidente con el descrito originalmente para la formulación de referencia, favorecido probablemente por la estricta técnica de administración. Es esencial una adecuada formación de los pacientes para optimizar el uso de CFOT, ya que los pacientes bien entrenados pueden sacar buen provecho de su flexibilidad para auto-regularse el alivio del dolor

Diet and feeding strategy of thornback ray Raja clavata.

The diet and feeding strategy of thornback ray Raja clavata, from the eastern-central Adriatic Sea, were investigated. Stomach contents of 428 specimens, total length (L(T)) of 14·0-75·1 cm, were collected from commercial bottom trawls. The prey items identified in the stomachs belong to eight major groups: Cephalopoda, Polychaeta, Stomatopoda, Decapoda (Natantia and Reptantia), Mysidacea, Isopoda, Amphipoda and Teleostei. Decapods were the most important prey (index of relative important, %I(RI) ,= 72·8) followed by teleosts (%I(RI) = 20·4), whereas other prey groups were only occasionally ingested. Small-sized individuals (<25 cm L(T)) fed primarily on small crustaceans (mysids and amphipods), whereas large-sized specimens consumed larger prey, such as decapods, cephalopods and teleosts. Diet composition showed little seasonal variation; decapods were the most important prey in all seasons. There was high dietary similarity between sampling locations. The percentage of empty stomachs did not differ significantly among size classes and seasons. In terms of composition by species, the diet of R. clavata was characterized by a variety of rare or unimportant prey. As a result, R. clavata could be considered a generalist predator.

Bilastine for the relief of allergy symptoms.

Bilastine is a potent inhibitor of the histamine H1 receptor. It was recently approved in 28 countries of the European Union for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria in adults and children older than 12 years. Data from preclinical studies confirmed its selectivity for the histamine H1 receptor over other receptors, and demonstrated antihistaminic and antiallergic properties in vivo. Studies in healthy volunteers and patients have shown that bilastine does not affect driving ability, cardiac conduction or alertness. Bilastine has demonstrated a good safety profile, without serious adverse effects or antimuscarinic effects in clinical trials. There were no significant changes in laboratory tests, electrocardiograms or vital signs. In clinical studies, oral treatment with bilastine 20 mg once daily improved allergic rhinitis with greater efficacy than placebo and comparable to cetirizine and desloratadine. Bilastine 20 mg was more effective than placebo and equivalent to levocetirizine in chronic urticaria, relieving symptoms, improving quality of life and controlling sleep disorders.

Reactive oxygen species mediate inflammatory cytokine release and EGFR-dependent mucin secretion in airway epithelial cells exposed to Pseudomonas pyocyanin.

Despite the long-appreciated in vivo role of the redox-active virulence factor pyocyanin in Pseudomonas airway infections and the importance of airway epithelial cells in combating bacterial pathogens, little is known about pyocyanin's effect on airway epithelial cells. We find that exposure of bronchiolar epithelial cells to pyocyanin results in MUC2/MUC5AC induction and mucin secretion through release of inflammatory cytokines and growth factors (interleukin (IL)-1ß, IL-6, heparin-bound epidermal growth factor, tissue growth factor-α, tumor necrosis factor-α) that activate the epidermal growth factor receptor pathway. These changes are mediated by reactive oxygen species produced by pyocyanin. Microarray analysis identified 286 pyocyanin-induced genes in airway epithelial cells, including many inflammatory mediators elevated in cystic fibrosis (granulocyte colony-stimulating factor (G-CSF), granulocyte-monocyte CSF, chemokine (C-X-C motif) ligand 1 (CXCL1), serum amyloid, IL-23) and several novel pyocyanin-responsive genes of potential importance in the infection process (IL-24, CXCL2, CXCL3, CCL20, CXCR4). This comprehensive study uncovers numerous details of pyocyanin's proinflammatory action and establishes airway epithelial cells as key responders to this microbial toxin.

Oral versus intravenous therapy in the treatment of systemic mycosis.

The great majority of systemic fungal infections require long-term therapy that often extends 6-12 months, particularly in immunosuppressed patients. It can be difficult to comply with this requirement when the drug to be used is only available for intravenous administration, because problems related to maintaining a permeable venous pathway for long periods arise. The availability of an intravenously (IV) and orally (PO) administered drug can solve this problem by making sequential therapy possible. Voriconazole is a new antifungal agent that, apart from satisfying this requirement because it has a high oral bioavailability, presents a broad spectrum of antifungal activity that makes its use possible, a priori, in the initial and/or sequential IV/PO treatment of any systemic mycotic infection. Based on current costs there is potential for savings compared with liposomal amphotericin B.

Farmacología de antimicrobianos utilizados en el tratamiento de las infecciones graves por bacterias grampositivas / Pharmacology of antimicrobials used in the treatment of serious Gram-positive bacteria infections

Los antimicrobianos con actividad frente a patógenos grampositivos (glucopéptidos, estreptograminas y oxazolidinonas) presentan diferencias farmacocinéticas que es importante conocer. Linezolid y teicoplanina pueden ser administrados por vía extravascular, al presentar una absorción adecuada. Este hecho permite su uso en terapia secuencial en pacientes que precisan tratamiento prolongado. La difusión de todos ellos al espacio extracelular es adecuada, incluso en el caso de teicoplanina debido al equilibrio existente entre la fracción de fármaco fijada y la no fijada a proteínas y su elevada semivida de eliminación. La eliminación de los glucopéptidos es casi exclusivamente renal, por lo que se precisa ajustar su posología en pacientes con deterioro renal. Quinupristina-dalfopristina y linezolid son eliminados en su mayor parte por metabolismo. El sistema CYP450 se encuentra implicado en la eliminación de las estreptograminas (AU)

Calcium signalling is altered in myeloid cells with a deficiency in NADPH oxidase activity.

The relation of O(2.-)-production and Ca2+ homeostasis was investigated in PLB-985 cell lines and neutrophilic granulocytes from peripheral blood. In differentiated wild-type PLB-985 cells, a high level of O(2.-)-production was associated with a significant decrease in the membrane potential and the inhibition of capacitative Ca2+ entry. These correlations were not observed in gp91phox -/- cells or in cells transfected with a non-functional mutant of gp91phox (Thr341Lys). Membrane depolarization and inhibition of Ca2+ entry reappeared in cells transfected with wild-type gp91phox. These experiments demonstrate that inhibition of Ca2+ entry depends on the presence of a functional NADPH oxidase. The Ca2+ signal induced by stimulation of chemotactic receptors also showed remarkable differences: [Ca2+]ic in the sustained phase was higher in gp91phox-/- than in wild-type cells. Alteration of the Ca2+ signal was reproduced by treating peripheral blood neutrophils with the NADPH oxidase inhibitor diphenylene-iodonium. It is concluded that the deficiency in O(2.-)-production is accompanied by significant alterations of Ca2+ homeostasis in myeloid cells.

[Pharmacology of antimicrobials used in the treatment of serious Gram-positive bacteria infections]. / Farmacología de antimicrobianos utilizados en el tratamiento de las infecciones graves por bacterias grampositivas.

Antimicrobials with specific activity against Gram-positive cocci (glycopeptides, oxazolidinones and streptogramins) have pharmacokinetic differences that are important to know. Linezolid and teicoplanin can be administered extravascularly due to their good bioavailability, allowing their use as sequential therapy in patients requiring prolonged treatment. All of these antimicrobials have an adequate distribution in extracellular tissues, even teicoplanin, due to the balance between the fraction that is bound and unbound to plasma proteins and its long terminal half-life. As the elimination of glycopeptides is almost exclusively renal, it is necessary to perform a posology adjustment in patients with renal failure. Quinupristin/dalfopristin and linezolid are metabolized by the liver, but CYP450 is only involved in streptogramin elimination.

Perfil de seguridad de las fluoroquinolonas / Safety profile of the fluoroquinolones

No disponible

Antiviral activities of pyrimidine nucleoside analogues: some structure--activity relationships.

Seventeen nucleoside derivatives (derived from arabinosylcytosine, resp. cytidine, 5-fluorouracil and uracil) were tested by agar-diffusion plaque-inhibition test for their antiviral activity with herpes simplex, vaccinia, fowl plague, Newcastle disease and western equine encephalomyelitis viruses. The highest antiviral activity against DNA viruses exhibited arabinosylcytosine, N4-acylarabinosylcytosines, arabinosylthiouracil, cyclocytidine and its 5'-chloroderivative. RNA viruses were inhibited by 5-fluorouridine only, whereas other tested compounds were ineffective or showing marginal activity only. By search for relationship between chemical structure and antiviral activity a tendency was found of higher antiviral activity at lower lipophilicity. This is probably due to better transport of the studied compounds into cell. The chemical structure, however, is the main reason of antiviral activity.

Rapid method for the detection of synergism in combinations of antiviral substances.

The plaque inhibition method was modified in order to evaluate the effectiveness of various combinations of antiviral substances. One substance (A) diffuses from the centre of cell culture, the other (B) is incorporated into the agar overlay at subinhibitory concentration. The inhibitory effect of the combination (A + B) is demonstrated by the increase in size of the inhibitory zone in comparison with the control inhibitory zone produced by the substance A alone. The ratio of the diameter of the inhibitory zone with substance combination (A + B) to the diameter of single drug control zone (substance A) serves as index DI (degree of interaction). Quantitative evaluation of the degree of potentiation using isobolograms showed that DI greater than 1.5 indicate a synergistic effect of the respective combinations. This inexpensive method can serve for rapid selection of suitable combinations out of number of substances. Model experiments were performed with combinations of selected inhibitors of virus replication.

Site of action of N,N'-bis(methylisatin-beta-thiosemicarbazone)-2-methylpiperazine in the vaccinia virus replication cycle.

N,N'-Bis(methylisatin-beta-thiosemicarbazone)-2-methylpiperazine inhibits late function or synthesis of a late component in the replication cycle of vaccinia virus. The kinetics of formation of the component sensitive to the inhibition with N,N'-bis(methylisatin-beta-thiosemicarbazone)-2-methylpiperazine precedes that of appearance of infectious virus by 30 min. The finding is in accord with the site of action of unsubstituted isatin-beta-thiosemicarbazone.

The role of cell type in transport and metabolic conversion of antiviral substances.

The transport and metabolic conversion of 6-azauridine differed when compared in HeLa and chick embryo (CE) cells. The values of 9-(S)-(2, 3-dihydroxypropyl) adenine transported into the cells were found different for ZP cells (rabbit lung cell line), HeLa and CE cells. These differences were less expressed if relating the values of cellular uptake and metabolic conversion to the cell volume of the respective cell type. The differences seem to play a role in quantitation of the antiviral potency of the compounds in different host cells.

Transport of antiviral agent 9-(S)-(2,3-dihydroxypropyl) adenine to animal cells.

Transport properties of 9-(S)-(2,3-dihydroxypropyl) adenine (DHPA) in cell cultures were studied. Transport of DHPA into chick embryo (CE), ZP (a cell line derived from rabbit lungs) and HeLa cells reached equilibrium values after 10 min incubation. The concentration of intracellular DHPA varied from 30 to 50 per cent of that in the medium. DHPA transport was only slightly affected during the lag phase of vaccinia virus replication. The opinion that DHPA is transported into the cell by facilitated diffusion, is supported 1) by the data on DHPA transport as a function of temperature and extracellular concentration, 2) by evidence of countertransport, 3) by temperature-dependent exit of DHPA, 4) by specific inhibition of DHPA transport in the presence of adenosine and deoxyadenosine and 5) by the fact that intracellular concentration of DHPA in equilibrium does not reach the concentration of DHPA in the medium. V and KM values varied in the range of 2-17 pmoles/min per 10(6) cells and 4-7 microM, respectively.